Targeting agents for enhancing radiation therapy
AssigneeSirius Medicine, LLC
InventorsMichael D. Weil, Kevin N. Morris, Rainer M. Malzbender
Life of this patent
Estimating the term…
Loading patent…
AssigneeSirius Medicine, LLC
InventorsMichael D. Weil, Kevin N. Morris, Rainer M. Malzbender
Estimating the term…
Targeting agents are provided that have an affinity for aberrant cells and tissues. These agents are comprised of chelates, ligands, and/or particles combined with high atomic weight elements so that treatment with ionizing electromagnetic radiation (X-rays, or Gamma rays) results in a higher dose to aberrant cells and tissues than other cells and tissues of a host. The invention further provide methods to enhance the tumor to normal tissue damage ratio by concentrating agents with high atomic number elements to the site of the tumor prior to administering radiotherapy. The result is greater therapeutic efficacy with fewer side effects. These compounds also permit diagnostic uses in combination with the therapeutic use.
A method to combine high Z elements for delivery to a tumor in order to enhance the effect of ionizing x-ray radiation therapy, comprising:
Dependencies are inferred from the claim text.